Psoriatic Disease

PHILADELPHIA — The efficacy of COVID-19 vaccinations is similar in patients with psoriatic disease compared non-psoriatic controls, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Interleukin-17 inhibition with bimekizumab yields strong joint and skin effects up to week 52 in patients with active psoriatic arthritis, according to data presented at ACR Convergence 2022.

SAN DIEGO — Domain-based or treat-to-target approaches can be effective in managing patients with complex psoriatic arthritis and avoiding “just trial and error,” according to a speaker at the Congress of Clinical Rheumatology West.

Inflammatory bowel disease was found to have a positive association with both psoriasis and psoriatic arthritis, suggesting it is a causal risk factor for these two chronic diseases, according to a study.

Among patients with similar psoriatic arthritis disease activity and therapy, women demonstrate higher levels of disease burden than men, according to data published in The Journal of Rheumatology.

Patients with psoriasis taking apremilast saw a 5% to 6% decrease in subcutaneous and visceral adiposity, indicating that the drug may benefit cardiometabolic health, according to a study.

Psoriasis is not only a disease that impacts patients physically, with scars and red patchy skin, but it also impacts patients emotionally. Patients’ mental health often suffer due to the anxieties of living with the condition.

MILAN — Patients with psoriasis who initially responded to bimekizumab maintained that response through 3 years with maintenance dosing, according to an open label long-term extension trial

Online forums, chatrooms and communities are often able help patients with chronic illness find comfort by connecting with other patients sharing their disease burden.

MILAN — Long-term treatment with risankizumab maintained efficacy in psoriatic arthritis through 100 weeks, according to a study presented at the European Academy of Dermatology and Venereology Congress.